A01 Stem cell signals in the initiation and progression of Non-Small Cell Lung Cancer. Alison Barber, University of California, San Diego School of Medicine, San Diego, CA, USA.


A03 Reversion of EMT sensitizes KRAS mutant cancers to MEK inhibition. David Peng, MD Anderson Cancer Center, Houston, TX, USA.


A05 Bronchial premalignant lesions have distinct molecular subtypes associated with future histologic progression. Jennifer Beane, Boston University School of Medicine, Boston, MA, USA.

A06 LINC00261 acts as a tumor suppressor in lung adenocarcinoma. Crystal Marconett, USC, Los Angeles, CA, USA.


A08 Widespread tobacco-smoking associated changes in DNA methylation and gene expression in lung tissue of smokers. Daniel Mullen, University of Southern California, Los Angeles, CA, USA.

A09; PR09 Alterations in cell junctions and neuroendocrine differentiation are key early steps in Crebbp/Ep300 mutation-driven SCLC development. Kwon-Sik Park, University of Virginia, Charlottesville, VA, USA.


A11 Developing a novel murine model of squamous cell dysplasia and squamous cell lung cancer that utilizes tobacco smoke exposure for use in chemoprevention. Meredith Tennis, University of Colorado Denver Anschutz Medical Center, Aurora, CO, USA.
A12 Non-small cell lung tumor-derived autoantibodies can distinguish benign from malignant pulmonary nodules. Kristin Lastwika, Fred Hutchinson Cancer Research Center, Seattle, WA, USA.

A13 Nanotechnology-enhanced mass spectrometry for the discovery and verification of risk biomarkers for Non-Small Cell Lung Cancer (NSCLC). Ruben Magni, George Mason University, Manassas, VA, USA.

A14 Changes in miRNA profile in a murine model of lung adenocarcinoma are attenuated by increased prostacyclin levels. Melissa New, University of Colorado, Aurora, CO, USA.

A15 Nasal gene expression for the diagnostic evaluation of indeterminate pulmonary nodules within a screening population. Kimberly Rieger-Christ, Lahey Hospital & Medical Center, Burlington, MA, USA.

A16 Sodium-dependent glucose transporter 2 is a novel diagnostic and therapeutic target for early-stage lung adenocarcinoma. Claudio Scafoglio, University of California Los Angeles, Los Angeles, CA, USA.

A17 Establishment of a unique patient derived tumor model positive for STRN-ALK fusion from a patient with stage IV lung adenocarcinoma. Jin Jen, Mayo Clinic, Rochester, MN, USA.

A18; PR02 Diagnostic and prognostic utility of urinary creatine riboside for early stage non-small cell lung cancer. Takahiro Oike, National Cancer Institute, Bethesda, MD, USA.

A19 Preliminary experience with liquid biopsies for NSCLC patients in a resource constrained setting: potential for change in management depends upon the timing!. Navneet Singh, PGIMER, Chandigarh, Chandigarh, India.

A20 Validation of the QuantStudio5 instrument for use in Biocept’s TargetSelectorTM ctDNA lung cancer assays. Veena Singh, Biocept, San Diego, CA, USA.

A21 High Throughput isolation of circulating tumor cells (CTCs) from Non-small cell lung cancer (NSCLC) patients for personalized treatments. Mina Zeinali, Chemical engineering, University of Michigan, Ann Arbor, MI, USA.

A23; PR08 Functional characterization and evolutionary reconstruction of small cell lung cancer transformation of EGFR-mutant lung adenocarcinomas. June-Koo Lee, Harvard Medical School, Boston, MA, USA.

A24 Using single cell RNAseq approaches to decipher heterogeneity in autochthonous mouse models of small cell lung cancer. Nemanja Marjanovic, MIT, Cambridge, MA, USA.

A25 Urokinase plasminogen activator expression is regulated by p53 harboring the lung cancer-specific mutation V157F. Julie Barta, Thomas Jefferson University, Philadelphia, PA, USA.


A27; PR01 Modeling Rb loss and pathway reactivation in lung adenocarcinoma. David Feldser, University of Pennsylvania, Philadelphia, PA, USA.

A28; PR12 A combined protein-protein interaction and genetic interaction map defines new and critical Kras effectors in non-small cell lung cancer. Peter Jackson, Stanford University School of Medicine, Stanford, CA, USA.

A29 The CUTO panel of patient-derived NSCLC cell lines reveals unique molecular characteristics and responses to targeted therapies. Anh Le, University of Colorado-Anschutz Medical Center, Aurora, CO, USA.

A30 Gene regulatory mechanisms governing invasive mucinous adenocarcinoma of the lung (IMA). Yutaka Maeda, Cincinnati Children's Hospital, Cincinnati, OH, USA.

A31 Loss of RNA editing of miR-99a-5p is a potential prognostic biomarker in completely resected lung adenocarcinoma. Keita Maemura, Department of Respiratory Medicine, The University of Tokyo Graduate School of Medicine, Tokyo, Japan.

A32 Prognostic stratification of stage I lung adenocarcinoma patients by HOXA9 promoter methylation ddPCR and blood vessel invasion analysis in FFPE tissues. Ana Robles, National Cancer Institute, Bethesda, MD, USA.


A34 Regulation of EGFR signaling by DRD1 in lung cancer. Brid Ryan, National Cancer Institute, Betheda, MD, USA.
A35 Vesicular secretion of suppressor of cytokine signaling 3 by alveolar macrophages is dysregulated in NSCLC and its provision inhibits tumor cell function. Jennifer Speth, University of Michigan, Ann Arbor, MI, USA.

A36 Establishment of patient-derived xenograft models of lung adenocarcinoma with two different EGFR mutations, L858R and exon19 deletion. Seiji Yano, Kanazawa University, Kanazawa, Ishikawa, Japan.

A37 Tobacco smoke increases lung adenocarcinoma risk by downregulating TGF-beta and AhR-regulated focal adhesion proteins involved in injury resolution. Theresa Ryan Stueve, USC, Los Angeles, CA, USA.